Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-cash Items: 2015-2022

  • Spyre Therapeutics' Non-cash Items rose 1145.81% to $4.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.1 million, marking a year-over-year increase of 1145.81%. This contributed to the annual value of $4.1 million for FY2022, which is 1145.81% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Non-cash Items of $4.1 million as of Q4 2022, which was up 1,145.81% from $328,000 recorded in Q4 2021.
  • Spyre Therapeutics' Non-cash Items' 5-year high stood at $4.8 million during Q4 2018, with a 5-year trough of $328,000 in Q4 2021.
  • In the last 3 years, Spyre Therapeutics' Non-cash Items had a median value of $3.8 million in 2020 and averaged $2.7 million.
  • In the last 5 years, Spyre Therapeutics' Non-cash Items tumbled by 91.34% in 2021 and then surged by 1,145.81% in 2022.
  • Over the past 5 years, Spyre Therapeutics' Non-cash Items (Quarterly) stood at $4.8 million in 2018, then dropped by 24.09% to $3.6 million in 2019, then climbed by 4.01% to $3.8 million in 2020, then tumbled by 91.34% to $328,000 in 2021, then spiked by 1,145.81% to $4.1 million in 2022.
  • Its last three reported values are $4.1 million in Q4 2022, $328,000 for Q4 2021, and $3.8 million during Q4 2020.